Stock Ratings / Health Care / NSRX / insiders

VERU (43) NNVC (33) EDSA (42) SCYX (34) ⌘ Pro Terminal →

Nasus Pharma Ltd. (NSRX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.19 -4.49% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.16

Nasus Pharma Ltd. (NSRX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $37.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.16 (-1.00%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NSRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY NSRX SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 38.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.51-9.4% Next Q

Q2 (-2Q)

Grade D$3.18+9.7% Next Q

Q3 (-1Q)

Grade E$3.49-8.6% Next Q

Current

Grade D-$3.19-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NSRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NSRX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.58) and Max Pain ($3.35) forces dealer call-delta covering toward $9.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NSRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NSRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NSRX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NSRX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NSRX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NSRX)

✓Walkthrough of NSRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NSRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.15%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.23H $3.27L $3.07C $3.19VOL 4.9K

RES: $4.10SUP: $3.05SMA50: $3.58SMA200: $3.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NSRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NSRX Butterfly Map → + Track NSRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NSRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NSRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NSRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NSRX)

Health Care Rank #793 of 1016 ⚔️ VERU vs NSRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NSRX vs. VERU, NNVC, EDSA, SCYX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nasus Pharma Ltd. (NSRX) ranks #793 by composite RQD confidence (36/100, grade D-) and #783 by equity capitalization ($37.4M). Within this direct 5-issuer industry benchmark cohort, NSRX leads on earnings valuation at N/A trailing P/E, while NSRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VERU currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with NSRX at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NSRX ACTIVE Nasus Pharma Ltd.	D-	36/100	—	—	-35.0%	-4.49%	$37.4M	Benchmark Subject
VERU Veru Inc.	D-	43/100	—	—	-35.0%	-1.76%	$38.0M	/veru-vs-nsrx →
NNVC NanoViricides Inc.	E	33/100	—	—	-35.0%	-1.38%	$36.5M	/nnvc-vs-nsrx →
EDSA Edesa Biotech Inc.	D-	42/100	—	—	-35.0%	+5.47%	$36.5M	/edsa-vs-nsrx →
SCYX SCYNEXIS Inc.	E	34/100	—	—	-35.0%	-2.28%	$38.4M	/scyx-vs-nsrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002029039

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nasus Pharma Ltd. (NSRX) reported GAAP revenue of $1.24B (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$5.9M, operating cash flow of -$4.9M, and free cash flow of -$4.9M (-641.7% YoY). On the balance sheet, NSRX closed FY2025 with $5.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.24B	-$5.9M	-$4.9M	-$4.9M	$5.0M	—
FY2024 (FY)	2024-12-31	$0	-$1.5M	-$665.0K	-$665.0K	$717.0K	—
FY2023 (FY)	2023-12-31	$0	-$1.1M	-$1.0M	-$1.0M	—	—

3. NSRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NSRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nasus Pharma Ltd. (NYSE: NSRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.19 (-4.49% 1D, market cap $37.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NSRX ranks #793 in composite RQD confidence.

How does NSRX compare to VERU and NNVC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NSRX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VERU (Veru Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $38.0M) and NNVC (NanoViricides Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M). Among the 5-stock peer group, NSRX leads on earnings multiple (N/A) while NSRX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NSRX?

Per NSRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002029039), Nasus Pharma Ltd. generated $1.24B in revenue, -$5.9M in net income, and -$4.9M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NSRX trading relative to its 50-day, 200-day, and 52-week technical levels?

NSRX last traded at $3.19 (-4.49% on volume of 10,578 shares), positioning the stock -10.89% below its 50-day simple moving average ($3.58) and -12.36% below its 200-day simple moving average ($3.64). Across its 52-week range of $1.98 to $9.50, NSRX sits at the 16.1% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.79 to $3.59).

NSRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are NSRX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NSRX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: NSRX RQD Cockpit NSRX 12M Forecast NSRX Earnings & Move NSRX Dividends & DRIP NSRX Insiders & 13F NSRX Whale Options NSRX Profit Sankey NSRX News & Why